Richard Callahan, MD
Child & Adolescent Psychiatry · Aventura, FLNPI 1215378336
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 31.3% of the total. Reporting peaked in 2019 at $216 and has fallen 89.6% since, to $22 in 2024. That places this record below the midpoint for child & adolescent psychiatry clinicians in FL, where the typical reported total is $446.
Across 19 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135
- Teva Pharmaceuticals USA, Inc.$89
- Johnson & Johnson$76
- Almatica Pharma LLC$42
- Sunovion Pharmaceuticals Inc.$23
- Alkermes, Inc.$23
- plus $45 from 2 others
What the payments were for
- Food & beverage$40193%
- Education$327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $135 |
| Teva Pharmaceuticals USA, Inc. | 4 | $89 |
| Johnson & Johnson | 4 | $76 |
| Almatica Pharma LLC | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $22 |
| Neuronetics, Inc. | 1 | $22 |
How this compares
$432 in reported general payments places this provider in the 45th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 34 | $714 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $451 |
| Clonazepam | 65 | $343 |
| Temazepam | 37 | $214 |
| Lorazepam | 16 | $125 |
| Alprazolam | 42 | $109 |
| Duloxetine Hcl | 13 | $85 |
| Zolpidem Tartrate | 18 | $83 |
| Quetiapine Fumarate | 15 | $82 |
| Fluoxetine Hcl | 14 | $43 |
| Diazepam | 20 | $40 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Aventura
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Bhaskar RajuOrlando$11K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.